Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

NCT00818649 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

16

Enrollment

OTHER

Sponsor class

Stopped Met protocol stop rule \[i.e., extreme toxicity\]

Conditions

Leukemia
Myelodysplastic Syndrome

Interventions

DRUG: bortezomib
DRUG: vorinostat

Sponsor

Masonic Cancer Center, University of Minnesota

Collaborators

[object Object]
[object Object]